@drbindiyamd's GLP-1 leptin claims need more evidence

What did @drbindiyamd actually say?

Dr. Gandhi says she uses leptin hormone levels as her primary lab marker for deciding when a patient should stay on or come off GLP-1 medication. Her framework is straightforward: "if and when your leptin hormone is high, you probably need to still be on this medication." When leptin starts coming down, that opens the conversation about tapering or stopping. She also mentions that dosing protocol, whether microdosing, weekly, or biweekly, factors into that decision.

To be clear about what she is not saying: she is not claiming leptin is the only factor, and she acknowledges it depends on the individual protocol. The framing is clinical and personalized, not prescriptive. That matters for how we evaluate this.

Does the science back this up?

Partially, but the evidence here is thinner than the confident framing suggests. Leptin resistance is a real and well-documented phenomenon in obesity research. People with obesity often have high circulating leptin but blunted hypothalamic signaling, a state described as leptin resistance. GLP-1 receptor agonists do appear to interact with leptin signaling pathways, but the relationship is indirect and not fully understood.

A 2022 paper by Clemmensen et al. in Cell Metabolism examined co-agonist approaches targeting both GLP-1 and leptin pathways, noting that these hormones interact in the hypothalamus. However, that work involved combination therapies, not standard GLP-1 monotherapy. A 2019 study by Zohar et al. in Obesity did find that semaglutide treatment was associated with reductions in leptin levels in patients with obesity, which is consistent with Dr. Gandhi's framework. But using serum leptin as a clinical decision tool for discontinuation of GLP-1 therapy is not currently supported by any major clinical guideline, including those from the Endocrine Society or the American Association of Clinical Endocrinology.

What did they get wrong (or right)?

She gets credit for rejecting the scale as the primary marker. That part is defensible. Body weight alone is a poor proxy for metabolic health, and there is legitimate scientific interest in using biomarkers to guide obesity pharmacotherapy decisions.

Where this gets shaky is the clinical operationalization. There is no standardized reference range for "high" vs. "normal" leptin in the context of GLP-1 discontinuation decisions. Leptin levels vary significantly by sex, body fat percentage, and time of day. A 2021 review by Pan and Myers in Nature Reviews Neuroscience noted that serum leptin concentration does not reliably reflect the degree of central leptin resistance, which is the functionally relevant problem. So even if a patient's serum leptin is trending down, that does not necessarily confirm their hypothalamic leptin sensitivity has been restored. Presenting this framework as a reliable clinical decision tool overstates what the current evidence actually supports.

What should you actually know?

GLP-1 receptor agonists like semaglutide and tirzepatide are chronic disease treatments, not short-course interventions. The STEP 4 trial (Rubino et al., 2021, JAMA) showed that patients who discontinued semaglutide regained most of their lost weight within a year. That context matters enormously when any clinician discusses "coming off" these medications.

Leptin as a biomarker is an interesting research area, not yet a validated clinical standard. If a provider is using it to guide GLP-1 decisions, patients should ask what reference ranges are being used, how resistance is being defined, and whether that approach is documented in any clinical protocol. That is not a reason to dismiss the idea outright, but it is a reason to ask harder questions. There is nothing wrong with a clinician developing a working clinical hypothesis around emerging science. The issue is when that hypothesis is presented as settled practice to a general audience of 10,000 people.